Cargando…
Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C
Direct-acting antiviral (DAA) therapy carries a potential risk of inducing hepatitis B virus (HBV) reactivation. However, the HBV kinetics during and after DAA therapy in patients co-infected with hepatitis C virus (HCV) and HBV remain unknown. We retrospectively evaluated the HBV kinetics during an...
Autores principales: | Sato, Shunsuke, Tsuzura, Hironori, Kita, Yuji, Ikeda, Yuji, Kabemura, Daishi, Sato, Sho, Amano, Nozomi, Yatagai, Noboru, Murata, Ayato, Shimada, Yuji, Genda, Takuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666226/ https://www.ncbi.nlm.nih.gov/pubmed/33994440 http://dx.doi.org/10.2169/internalmedicine.7337-21 |
Ejemplares similares
-
Post‐treatment serum Wisteria floribunda agglutinin‐positive mac‐2‐binding protein level is a useful predictor of hepatocellular carcinoma development after hepatitis C virus eradication
por: Sato, Shunsuke, et al.
Publicado: (2021) -
Does restricting fluid volume impact post-ERCP pancreatitis in patient with heart disease?
por: Tomishima, Ko, et al.
Publicado: (2021) -
On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy
por: Murata, Ayato, et al.
Publicado: (2020) -
Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication
por: Murata, Ayato, et al.
Publicado: (2016) -
Eosinophilic Gastroenteritis in an Ulcerative Colitis Patient During Treatment with Tumor Necrosis Factor-alpha Antagonist
por: Hayashida, Sho, et al.
Publicado: (2020)